AHA to CMS: Eliminate all-or-nothing approach to MU

The American Hospital Association is asking the Centers for Medicare & Medicaid Services (CMS) to eliminate the "all-or-nothing approach" to Meaningful Use.

A letter addressed to CMS Acting Principal Deputy Administrator Patrick Conway, MD, from the AHA calls the policy "misguided." The complexity of MU criteria is "overly burdensome" and not required by statute, contends the AHA.

“[W]e believe that CMS possesses the authority to eliminate the all-or-nothing approach to Meaningful Use and that the agency should do so by allowing providers that attest to meeting 70 percent of the Meaningful Use requirements to be designated as meaningful users,” wrote Ashley Thompson, AHA senior vice president of public policy analysis and development. “…It is clear that the statutory definition of meaningful EHR user permits CMS to employ the more flexible approach advocated by the AHA and others.”

AHA thanked CMS for flexibility in 2014 and 2015 meaningful use requirements, which supported providers in their ongoing work to adopt and use EHRs. AHA has consistently urged CMS to allow providers to implement a percentage or limited number of the meaningful use objectives and offer providers greater flexibility in meeting program requirements, especially for providers who work hard to meet the requirements but just miss out. 

Read the letter.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.